首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1451795

2024-2032 年获得性孤儿血液疾病治疗市场报告（按治疗方法、疾病适应症、配销通路和地区划分）

Acquired Orphan Blood Diseases Therapeutics Market Report by Therapy, Disease Indication, Distribution Channel, and Region 2024-2032

出版日期: 2024年03月02日 | 出版商:

IMARC | 英文 143 Pages | 商品交期: 2-3个工作天内

价格

简介目录图表

2023年，全球孤儿血液疾病治疗药物市场规模达到88亿美元。展望未来， IMARC Group预计到2032年该市场将达到172亿美元，2024-2032年复合年增长率（CAGR）为7.5%。个人中血液相关疾病的盛行率不断上升、政府的积极倡议以及全球医疗基础设施的改善是推动市场发展的一些关键因素。

后天性孤儿血液疾病是一种罕见的血液疾病，是由于血液中无法产生红血球 (RBC) 或红血球不足引起的。它们包括许多疾病，如骨髓增生异常症候群（MDS）、特发性血小板减少性紫斑症（ITP）、阵发性睡眠性血红蛋白尿（PNH）、骨髓纤维化（MF）、真性红血球增多症（PV ）和后天性粒细胞缺乏症。它们会导致骨髓功能异常并减少血小板数量。由于它们可以透过多种疗法进行治疗，例如重组因子、免疫球蛋白输注疗法、活化凝血酶原复合物浓缩物和血小板生成素受体激动剂，因此全球对获得性孤儿血液疾病疗法的需求正在上升。

后天性孤儿血液疾病治疗市场趋势：

目前，大众对血液疾病及其治疗方案的认识不断提高，加上全球个人收入水准的不断提高，是对市场产生正面影响的主要因素之一。此外，由于老年人口的增加，对血液疾病治疗方案的需求不断增长，正在加强市场的成长。据此，各国的管理机构和私人组织正在透过传播人们对血液相关疾病发生的认识来鼓励采用血液疾病治疗方法，并在世界各地提供多项医疗保健倡议，从而推动市场的成长。除此之外，由于全球各种血液相关疾病的盛行率不断增加，血液疾病治疗方法的采用越来越多，这提供了积极的市场前景。此外，透过世界各地的线上和线下药局广泛获得孤儿血液疾病治疗药物也促进了市场的成长。除此之外，个人对个人化药物的需求不断增长，以及全球医疗保健基础设施的改善，为行业投资者提供了利润丰厚的成长机会。除此之外，全球个人对具有成本效益和优质护理解决方案的需求不断增加。再加上越来越多地采用预防性护理和健康服务来避免疾病在个人中广泛传播，正在推动市场的成长。此外，主要製造商正在为镰状细胞性贫血儿科患者推出基于羟基脲的治疗方法，这支持了市场的成长。

本报告回答的关键问题：

迄今为止，全球获得性孤儿血液疾病治疗市场表现如何，未来几年将如何表现？
全球获得性孤儿血液疾病治疗市场的驱动因素、限制因素和机会是什么？
每个驱动因素、限制因素和机会对全球获得性孤儿血液疾病治疗市场有何影响？
主要区域市场有哪些？
哪些国家代表了最具吸引力的后天孤儿血液疾病治疗市场？
基于该疗法的市场区隔是什么？
获得性孤儿血液疾病治疗市场中哪种疗法最具吸引力？
根据疾病迹象，市场的细分是什么？
后天孤儿血液疾病治疗市场中最具吸引力的疾病适应症是什么？
基于配销通路的市场区隔是什么？
获得性孤儿血液疾病治疗市场中哪个配销通路最具吸引力？
全球获得性孤儿血液疾病治疗市场的竞争结构如何？
全球获得性孤儿血液疾病治疗市场的主要参与者/公司有哪些？

后天性粒细胞缺乏症
- 市场走向
- 市场预测
后天性血友病
- 市场走向
- 市场预测
后天性血管性血友病症候群
- 市场走向
- 市场预测
阵发性睡眠性血红素尿症 (PNH)
- 市场走向
- 市场预测
骨髓造血不良症候群
- 市场走向
- 市场预测
其他的
- 市场走向
- 市场预测

第 8 章：市场区隔：按配销通路

医院药房
- 市场走向
- 市场预测
零售药房
- 市场走向
- 市场预测
其他的
- 市场走向
- 市场预测

第 9 章：市场区隔：按地区

北美洲
- 美国
  - 市场走向
  - 市场预测
- 加拿大
  - 市场走向
  - 市场预测
亚太
- 中国
  - 市场走向
  - 市场预测
- 日本
  - 市场走向
  - 市场预测
- 印度
  - 市场走向
  - 市场预测
- 韩国
  - 市场走向
  - 市场预测
- 澳洲
  - 市场走向
  - 市场预测
- 印尼
  - 市场走向
  - 市场预测
- 其他的
  - 市场走向
  - 市场预测
欧洲
- 德国
  - 市场走向
  - 市场预测
- 法国
  - 市场走向
  - 市场预测
- 英国
  - 市场走向
  - 市场预测
- 义大利
  - 市场走向
  - 市场预测
- 西班牙
  - 市场走向
  - 市场预测
- 俄罗斯
  - 市场走向
  - 市场预测
- 其他的
  - 市场走向
  - 市场预测
拉丁美洲
- 巴西
  - 市场走向
  - 市场预测
- 墨西哥
  - 市场走向
  - 市场预测
- 其他的
  - 市场走向
  - 市场预测
中东和非洲
- 市场走向
- 市场细分：按国家/地区
- 市场预测

第 10 章：驱动因素、限制与机会

概述
司机
限制
机会

第 11 章：价值链分析

第 12 章：波特五力分析

概述
买家的议价能力
供应商的议价能力
竞争程度
新进入者的威胁
替代品的威胁

第 13 章：价格分析

第14章：竞争格局

市场结构
关键参与者
关键参与者简介
- Alexion Pharmaceuticals Inc. (AstraZeneca plc)
- Amgen Inc.
- GSK plc
- Novartis AG
- Novo Nordisk A/S
- Otsuka Pharmaceutical Co. Ltd.
- Rigel Pharmaceuticals Inc.
- Roche Holding AG
- Sanofi
- Takeda Pharmaceutical Company Limited

简介目录图表

Product Code: SR112024A8217

The global acquired orphan blood diseases therapeutics market size reached US$ 8.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032. The growing prevalence of blood-related disorders among individuals, favorable government initiatives, and improving healthcare infrastructure worldwide represent some of the key factors driving the market.

Acquired orphan blood diseases are rare blood conditions that are caused by an inability to produce red blood cells (RBCs) or their insufficiency in the blood. They comprise numerous diseases, such as myelodysplastic syndrome (MDS), idiopathic thrombocytopenic purpura (ITP), paroxysmal nocturnal hemoglobinuria (PNH), myelofibrosis (MF), polycythemia vera (PV), and acquired agranulocytosis. They can cause improper functioning of bone marrow and can decrease the number of platelets. As they can be treated through several therapies, such as recombinant factor, immunoglobulin infusion therapy, activated prothrombin complex concentrate, and thrombopoietin receptor agonists, the demand for acquired orphan blood disease therapeutics is rising across the globe.

Acquired Orphan Blood Diseases Therapeutics Market Trends:

At present, the increasing awareness about blood diseases and their treatment options among the masses, along with the inflating income level of individuals worldwide, represents one of the major factors influencing the market positively. Moreover, the rising demand for blood disease therapeutics options due to the increasing geriatric population is strengthening the growth of the market. In line with this, governing agencies and private organizations of various countries are encouraging the adoption of blood disease therapeutics by spreading awareness about the occurrence of blood-associated disorders among individuals and offering several healthcare initiatives around the world is impelling the growth of the market. Apart from this, the growing adoption of blood disease therapeutics due to the increasing prevalence of various blood-related disorders among individuals across the globe is offering a positive market outlook. Additionally, the wide availability of acquired orphan blood disease therapeutics drugs through online and offline pharmacy stores around the world is contributing to the growth of the market. Besides this, the increasing demand for personalized medicines among individuals, along with the improving healthcare infrastructure worldwide, is offering lucrative growth opportunities to industry investors. In addition to this, there is a rise in the demand for cost-effective and quality care solutions among individuals across the globe. This, coupled with the increasing adoption of preventative care and wellness services to avoid widespread disease among individuals, is bolstering the growth of the market. Furthermore, key manufacturers are introducing hydroxyurea-based treatment for pediatric patients with sickle cell anemia, which is supporting the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global acquired orphan blood diseases therapeutics market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on therapy, disease indication, and distribution channel.

Therapy Insights:

Recombinant Factor

Immunoglobulin Infusion Therapy

Activated Prothrombin Complex Concentrate

Thrombopoietin Receptor Agonists

Others

The report has provided a detailed breakup and analysis of the acquired orphan blood diseases therapeutics market based on the therapy. This includes recombinant factor, immunoglobulin infusion therapy, activated prothrombin complex concentrate, thrombopoietin receptor agonists, and others.

Disease Indication Insights:

Acquired Agranulocytosis

Acquired Hemophilia

Acquired Von Willebrand Syndrome

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Myelodysplastic Syndrome

Others

A detailed breakup and analysis of the acquired orphan blood diseases therapeutics market based on the disease indication has also been provided in the report. This includes acquired agranulocytosis, acquired hemophilia, acquired von willebrand syndrome, paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome, and others. According to the report, acquired hemophilia accounted for the largest market share.

Distribution Channel Insights:

Hospital Pharmacy

Retail Pharmacy

Others

A detailed breakup and analysis of the acquired orphan blood diseases therapeutics market based on the distribution channel has also been provided in the report. This includes hospital pharmacy, retail pharmacy, and others. According to the report, hospital pharmacy accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for acquired orphan blood diseases therapeutics. Some of the factors driving the North America acquired orphan blood diseases therapeutics market included the growing awareness about several treatment options, wide availability of therapeutic drugs, favorable government initiatives, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global acquired orphan blood diseases therapeutics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Alexion Pharmaceuticals Inc. (AstraZeneca plc), Amgen Inc., GSK plc, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co. Ltd., Rigel Pharmaceuticals Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

How has the global acquired orphan blood diseases therapeutics market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global acquired orphan blood diseases therapeutics market?
What is the impact of each driver, restraint, and opportunity on the global acquired orphan blood diseases therapeutics market?
What are the key regional markets?
Which countries represent the most attractive acquired orphan blood diseases therapeutics market?
What is the breakup of the market based on the therapy?
Which is the most attractive therapy in the acquired orphan blood diseases therapeutics market?
What is the breakup of the market based on the disease indication?
Which is the most attractive disease indication in the acquired orphan blood diseases therapeutics market?
What is the breakup of the market based on the distribution channel?
Which is the most attractive distribution channel in the acquired orphan blood diseases therapeutics market?
What is the competitive structure of the global acquired orphan blood diseases therapeutics market?
Who are the key players/companies in the global acquired orphan blood diseases therapeutics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Acquired Orphan Blood Diseases Therapeutics Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Therapy

6.1 Recombinant Factor
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Immunoglobulin Infusion Therapy
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Activated Prothrombin Complex Concentrate
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Thrombopoietin Receptor Agonists
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast

7 Market Breakup by Disease Indication

7.1 Acquired Agranulocytosis
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Acquired Hemophilia
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Acquired Von Willebrand Syndrome
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Paroxysmal Nocturnal Hemoglobinuria (PNH)
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Myelodysplastic Syndrome
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast

8 Market Breakup by Distribution Channel

8.1 Hospital Pharmacy
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Retail Pharmacy
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Alexion Pharmaceuticals Inc. (AstraZeneca plc)
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
- 14.3.2 Amgen Inc.
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
  - 14.3.2.4 SWOT Analysis
- 14.3.3 GSK plc
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
  - 14.3.3.4 SWOT Analysis
- 14.3.4 Novartis AG
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 Financials
  - 14.3.4.4 SWOT Analysis
- 14.3.5 Novo Nordisk A/S
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
  - 14.3.5.4 SWOT Analysis
- 14.3.6 Otsuka Pharmaceutical Co. Ltd.
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
- 14.3.7 Rigel Pharmaceuticals Inc.
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
  - 14.3.7.4 SWOT Analysis
- 14.3.8 Roche Holding AG
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
- 14.3.9 Sanofi
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 Financials
  - 14.3.9.4 SWOT Analysis
- 14.3.10 Takeda Pharmaceutical Company Limited
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
  - 14.3.10.3 Financials
  - 14.3.10.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

简介目录图表

List of Figures

Figure 1: Global: Acquired Orphan Blood Diseases Therapeutics Market: Major Drivers and Challenges
Figure 2: Global: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Therapy (in %), 2023
Figure 5: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Disease Indication (in %), 2023
Figure 6: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Distribution Channel (in %), 2023
Figure 7: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Region (in %), 2023
Figure 8: Global: Acquired Orphan Blood Diseases Therapeutics (Recombinant Factor) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Acquired Orphan Blood Diseases Therapeutics (Recombinant Factor) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Acquired Orphan Blood Diseases Therapeutics (Immunoglobulin Infusion Therapy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Acquired Orphan Blood Diseases Therapeutics (Immunoglobulin Infusion Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Acquired Orphan Blood Diseases Therapeutics (Activated Prothrombin Complex Concentrate) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Acquired Orphan Blood Diseases Therapeutics (Activated Prothrombin Complex Concentrate) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Acquired Orphan Blood Diseases Therapeutics (Thrombopoietin Receptor Agonists) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Acquired Orphan Blood Diseases Therapeutics (Thrombopoietin Receptor Agonists) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Acquired Orphan Blood Diseases Therapeutics (Other Therapies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Acquired Orphan Blood Diseases Therapeutics (Other Therapies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Agranulocytosis) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Agranulocytosis) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Hemophilia) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Hemophilia) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Von Willebrand Syndrome) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Von Willebrand Syndrome) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Acquired Orphan Blood Diseases Therapeutics (Paroxysmal Nocturnal Hemoglobinuria (PNH)) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Acquired Orphan Blood Diseases Therapeutics (Paroxysmal Nocturnal Hemoglobinuria (PNH)) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Acquired Orphan Blood Diseases Therapeutics (Myelodysplastic Syndrome) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Acquired Orphan Blood Diseases Therapeutics (Myelodysplastic Syndrome) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Global: Acquired Orphan Blood Diseases Therapeutics (Other Disease Indications) Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Global: Acquired Orphan Blood Diseases Therapeutics (Other Disease Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Global: Acquired Orphan Blood Diseases Therapeutics (Hospital Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Global: Acquired Orphan Blood Diseases Therapeutics (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Global: Acquired Orphan Blood Diseases Therapeutics (Retail Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Global: Acquired Orphan Blood Diseases Therapeutics (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Global: Acquired Orphan Blood Diseases Therapeutics (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Global: Acquired Orphan Blood Diseases Therapeutics (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: North America: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: North America: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: United States: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: United States: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: Canada: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: Canada: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Asia-Pacific: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Asia-Pacific: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: China: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: China: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Japan: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Japan: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: India: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: India: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: South Korea: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: South Korea: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Australia: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Australia: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: Indonesia: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: Indonesia: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Others: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Others: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Europe: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Europe: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Germany: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Germany: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: France: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: France: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: United Kingdom: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: United Kingdom: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Italy: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Italy: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: Spain: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: Spain: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Russia: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Russia: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: Others: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: Others: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: Latin America: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: Latin America: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 76: Brazil: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 77: Brazil: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 78: Mexico: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 79: Mexico: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 80: Others: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 81: Others: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 82: Middle East and Africa: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 83: Middle East and Africa: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Country (in %), 2023
Figure 84: Middle East and Africa: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 85: Global: Acquired Orphan Blood Diseases Therapeutics Industry: Drivers, Restraints, and Opportunities
Figure 86: Global: Acquired Orphan Blood Diseases Therapeutics Industry: Value Chain Analysis
Figure 87: Global: Acquired Orphan Blood Diseases Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Acquired Orphan Blood Diseases Therapeutics Market: Key Industry Highlights, 2023 & 2032
Table 2: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Therapy (in Million US$), 2024-2032
Table 3: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Disease Indication (in Million US$), 2024-2032
Table 4: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 5: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Acquired Orphan Blood Diseases Therapeutics Market: Competitive Structure

02-2729-4219

+886-2-2729-4219